bioRxivImmunologyPreprint
Pre-existing YFV-17D immunity mediates T cell cross-protection against DENV-2 infection
Prince Baffour TontoiD, Sebastian Gallon, Reem AlatrashiD, Wei‐Kung WangiD, Bobby Brooke HerreraiD
Abstract
Widespread yellow fever virus (YFV) immunity in Sub-Saharan Africa may mitigate orthoflavivirus outbreaks. Here, we investigate whether pre-existing YFV-17D immunity confers cross-protection against dengue virus serotype 2 (DENV-2) in a murine model. IFNAR1-/- mice immunized with YFV-17D exhibited significantly reduced DENV-2 viremia, weight loss, and disease severity, with improved survival compared to YFV-naive controls. Mechanistic studies revealed that cross-protection was mediated by heterologous T cell responses rather than cross-neutralizing antibodies. Depletion of T cells in YFV-17D-immune mice prior to DENV-2 challenge resulted in increased viremia, weight loss, and disease severity, underscoring the protective role of YFV-17D-elicited T cell immunity. Furthermore, YFV-17D-specific T cells displayed cytotoxicity against DENV NS3- and NS5-pulsed cells, demonstrating their functional role in viral control. These findings highlight the critical contribution of heterologous T cell immunity in YFV-17D-mediated protection against DENV-2 and suggest that vaccines designed to elicit T cell responses could enhance cross-protection against orthoflavivirus infections.
- organism: mouse
- research focus: host-pathogen & immune response
- research focus: cell signaling & trafficking
- research focus: cell type annotation
- research focus: cell-cell communication
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Prior flavivirus immunity skews the yellow fever vaccine response to expand cross-reactive antibodies with increased risk of antibody dependent enhancement of Zika and dengue virus infection
A. Santos-Peral, F. Luppa, … S. Rothenfusser·bioRxiv·May 7, 2023
- T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species.
A. Grifoni, H. Voic, … A. Sette·bioRxiv·Jan 17, 2020
- Live attenuated YFV-17D vaccine induces robust B and T cell immunity in vaccine-draining lymph nodes
Rachel B Evans, Wen Shi Lee, … Adam K Wheatley·bioRxiv·Nov 5, 2026
- Yellow Fever Emergence: Role of Heterologous Flavivirus Immunity in Preventing Urban Transmission
D. P. Shinde, J. A. Plante, … S. C. Weaver·bioRxiv·Mar 3, 2024
- A chimeric Japanese encephalitis vaccine protects against lethal yellow fever virus infection without inducing neutralizing antibodies
N. Mishra, R. Boudewijns, … K. Dallmeier·bioRxiv·Jul 28, 2019
- Longitudinal Profiling of CD4⁺ T Cell Responses Following de novo Yellow Fever Vaccination
Dzenis Gojak, Maria S. Kuznetsova, … Benson Ogunjimi·bioRxiv·Feb 28, 2026